359 related articles for article (PubMed ID: 25242168)
1. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
3. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
8. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.
Sun Y; Sun L; An Y; Shen X
Med Sci Monit; 2015 Aug; 21():2316-21. PubMed ID: 26255947
[TBL] [Abstract][Full Text] [Related]
11. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
[TBL] [Abstract][Full Text] [Related]
14. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.
Ai J; Chen Y; Peng X; Ji Y; Xi Y; Shen Y; Yang X; Su Y; Sun Y; Gao Y; Ma Y; Xiong B; Shen J; Ding J; Geng M
Mol Cancer Ther; 2018 Apr; 17(4):751-762. PubMed ID: 29237805
[TBL] [Abstract][Full Text] [Related]
17. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
18. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
19. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
